安全性问题促使马吉妥昔单抗临床试验暂停。
Safety Concerns Prompt Pause of Magrolimab Trials.
出版信息
Cancer Discov. 2022 Apr 1;12(4):877-878. doi: 10.1158/2159-8290.CD-NB2022-0012.
Abstract
Gilead paused enrollment in trials of its anti-CD47 therapy magrolimab following suspicions of a safety issue experienced by patients with acute myeloid leukemia or myelodysplastic syndrome who received it in combination with the chemotherapeutic agent azacitidine.
摘要
吉利德暂停了其抗 CD47 疗法 magrolimab 的试验入组，原因是怀疑接受该药与化疗药物阿扎胞苷联合治疗的急性髓系白血病或骨髓增生异常综合征患者出现了安全问题。
Zotero 插件